ArticleFrontiers in oncology2023

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.

Jia-Xin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.